Kidney Cancer UK
Leeds cancer nurse wins inaugural Melinda Whale Memorial Award 2019
A Leeds nurse was the first to receive a high-profile award recognising her dedication, care and unwavering support for kidney cancer patients.... Read More
Plans to ease guidance for over 2 million shielding
Advisory guidance to be eased for 2.2 million clinically extremely vulnerable people across England, as virus infection rates continue to fall From... Read More
Analysis findings from KEYNOTE-427 ccRCC trial
In an interview with Targeted Oncology, Scott Tykodi, MD, PhD, a physician with the Seattle Cancer Care Alliance, and associate professor in... Read More
Researchers underscore efficacy of Pembrolizumab+Axitinib in treating advanced Rcc
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma Researchers at Fox Chase Cancer Center, along... Read More
How GP’s should support ‘Shielded’ Patients
Patients who are most at risk of severe complications from COVID-19 have been asked to ‘shield’ themselves. This means that they should... Read More
Cancer patients to get surgery in ‘Covid-free’ hubs
Thousands of cancer patients will be operated on at new “Covid-free” hubs in hospitals across England as the NHS consolidates urgent surgery in fewer... Read More
Seek help if you show cancer symptoms, urge NHS
NHS WARNING TO SEEK HELP FOR CANCER SYMPTOMS, AS HALF OF PUBLIC REPORT CONCERNS WITH GETTING CHECKED England’s top cancer doctor has... Read More
Pexa-Vec with immunotherapy reduced tumor in 75% of RCC patients
San Francisco based SillaJen Biotherapeutics said a combination of its oncolytic viral therapy Pexa-Vec (JX-594) with immune check inhibitor Libtayo (ingredient: cemiplimab)... Read More
Covid-19 vulnerable patient list balloons by 500,000
The number of patients asked to “shield” themselves from coronavirus is expected to reach two million by the end of the month,... Read More
Cryoablation Safe, Efficacious for Small Renal Tumors
Image-guided percutaneous cryoablation is a safe and efficacious treatment for selected small renal cell carcinoma (RRC) tumors, new findings published in the... Read More
Drug combo hits targets in first-line RCC trial
Bristol Myers Squibb and Exelixis have announced that a late-stage study testing a combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) has hit... Read More
Create covid-free hubs for cancer patients, Trusts told
Trusts have been told to urgently reconfigure surgical cancer services into covid-free hubs to minimise the number of procedures being postponed. In... Read More
BBC’s George Alagiah on living with coronavirus and cancer
In these worrying times we live in, this is a positive story for all cancer patients. BBC newsreader George Alagiah, who is... Read More
Weak kidney cancer cells could serve as therapeutic target
Researchers at the University of Texas MD Anderson Cancer Center have made an important discovery about how some cancers rely on glucose... Read More
RAMPART UPDATE: Covid-19 Participant Information
The team of doctors and researchers responsible for the RAMPART study are reviewing the potential risks and benefit of the research on... Read More
Nivolumab+Sitravatinib Combo Impresses in RCC
Combining a broad-spectrum tyrosine kinase inhibitor (TKI) with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary... Read More
Kidney Cancer Accord: Consensus Statement
A pathway forward
Grant Stewart New Chair of Surgical Oncology, University of Cambridge
We are delighted to announce that Grant Stewart, Chair of Kidney Cancer UK’s ‘Kidney Cancer Accord‘ steering group, is to take up... Read More
Hopes of ‘one-size-fits-all’ cancer therapy discovered
London: Researchers at Cardiff University have discovered a new type of killer T-cell that offers hope of a “one-size-fits-all” cancer therapy. These... Read More
Tivozanib Shows Superior Safety Profile Across TKIs in mRCC
For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies... Read More
Non-invasive test that can detect kidney cancer
Renal cell carcinoma (RCC) has poor survival prognosis because it is asymptomatic at an early, more curative stage. Recently, urine perilipin-2 (PLIN-2)... Read More
Folic acid reduces mucositis in mRCC
With the introduction of tyrosine kinase inhibitors (TKI) and mTOR-inhibitors a decade ago, many metastatic RCC patients have received their treatment as... Read More
EC approves Bavencio combination
Merck and Pfizer have announced that the European Commission (EC) has approved Bavencio in combination with axitinib for the first-line treatment of... Read More
Recurrence of RCC after Robotic surgery
WCE 2019: Local Regional Recurrence of RCC after Robotic Partial Nephrectom Abu Dhabi, United Arab Emirates (UroToday.com) Mr. Ethan Wajswol began by introducing... Read More
